Stock listing

NASDAQ:OKYO OKYO Pharma Limited Stock

Home listing (NASDAQ) of OKYO Pharma Limited

Follow OKYO Pharma Limited into a list and get an email when it puts out news.

Share price · NASDAQ:OKYO

$1.07 USD -0.03 (-2.7%)

Close on Nov 20, 2026

Past year -44.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.04 – $1.25 USDNov 20, 2026
Volume
76,391 sharesNov 20, 2026
Market cap
$56.15M USDAt the close on Nov 20, 2026 · price × 52.48M shares outstanding
52-week range
$1.04 – $3.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$169,207 USDMedian day 60,230 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
OKYO Pharma Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:OKYO · Home$1.07 USD-0.03 (-2.7%)76,391$1.13$1.25$1.04$1.10Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OKYO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.07-0.03-2.7%$1.13$1.25$1.0476,391
$1.10-0.005-0.5%$1.10$1.14$1.08235,407
$1.105-0.07-6.0%$1.18$1.20$1.105167,321
$1.175-0.175-13.0%$1.30$1.345$1.153,710,017
$1.35-0.05-3.6%$1.41$1.41$1.204264,095
$1.40-0.02-1.4%$1.39$1.41$1.33119,416
$1.42+0.04+2.9%$1.357$1.449$1.31159,877
$1.38+0.10+7.8%$1.29$1.407$1.29104,256
$1.28-0.15-10.5%$1.40$1.42$1.28118,455
$1.43+0.03+2.1%$1.40$1.46$1.28293,889
$1.40-0.03-2.1%$1.41$1.41$1.3550,490
$1.43-0.02-1.4%$1.48$1.519$1.3694,428
$1.45-0.01-0.7%$1.448$1.465$1.4126,869
$1.46-0.01-0.7%$1.46$1.50$1.3691,929
$1.47-0.03-2.0%$1.46$1.49$1.40107,088
$1.50+0.01+0.7%$1.46$1.51$1.4618,806
$1.490.000.0%$1.48$1.535$1.4024,651
$1.49+0.05+3.5%$1.475$1.51$1.4111,310
$1.44+0.04+2.9%$1.40$1.44$1.3916,653
$1.40-0.07-4.8%$1.46$1.47$1.4013,800
$1.47-0.07-4.5%$1.50$1.50$1.3872,500
$1.54+0.17+12.4%$1.52$1.65$1.43241,000
$1.37-0.03-2.1%$1.41$1.42$1.3748,200
$1.40-0.01-0.7%$1.382$1.42$1.3824,100
$1.41-0.02-1.4%$1.43$1.43$1.4025,600
$1.43+0.015+1.1%$1.42$1.46$1.4048,900
$1.415-0.023-1.6%$1.45$1.45$1.3818,500
$1.438-0.002-0.1%$1.46$1.47$1.4120,900
$1.44+0.02+1.4%$1.46$1.49$1.4070,400
$1.42+0.03+2.2%$1.40$1.53$1.35115,500
$1.39-0.02-1.4%$1.43$1.46$1.3527,500
$1.41-0.05-3.4%$1.45$1.48$1.3633,700
$1.46-0.01-0.7%$1.48$1.49$1.4630,400
$1.470.000.0%$1.46$1.47$1.4311,200
$1.47+0.13+9.7%$1.33$1.47$1.3382,500
$1.34+0.05+3.9%$1.29$1.345$1.26516,900
$1.29-0.07-5.1%$1.34$1.36$1.296,000
$1.36-0.01-0.7%$1.30$1.37$1.3044,000
$1.37-0.01-0.7%$1.355$1.39$1.31141,700
$1.380.000.0%$1.36$1.40$1.3287,700
$1.38+0.06+4.5%$1.33$1.39$1.3087,100
$1.32-0.03-2.2%$1.37$1.37$1.3085,200
$1.35+0.02+1.5%$1.34$1.38$1.3198,700
$1.33-0.03-2.2%$1.38$1.41$1.286127,900
$1.36+0.04+3.0%$1.32$1.44$1.3222,100
$1.32-0.01-0.8%$1.33$1.395$1.28555,700
$1.33-0.01-0.7%$1.36$1.42$1.2886,000
$1.34-0.06-4.3%$1.42$1.43$1.3283,300
$1.400.000.0%$1.38$1.455$1.35133,800
$1.40-0.03-2.1%$1.46$1.47$1.3953,700
$1.43-0.02-1.4%$1.40$1.47$1.40145,900
$1.45-0.08-5.2%$1.53$1.53$1.3980,200
$1.53-0.04-2.5%$1.56$1.59$1.395275,700
$1.57+0.02+1.3%$1.55$1.595$1.5232,600
$1.55-0.07-4.3%$1.62$1.62$1.5219,300
$1.62+0.11+7.3%$1.516$1.66$1.51691,500
$1.51-0.01-0.7%$1.52$1.55$1.5122,300
$1.52-0.15-9.0%$1.65$1.669$1.5163,900
$1.67+0.12+7.7%$1.599$1.67$1.48135,400
$1.550.000.0%$1.54$1.58$1.5357,300
$1.55-0.01-0.6%$1.55$1.58$1.536,400
$1.56+0.06+4.0%$1.52$1.62$1.4960,230
$1.50-0.04-2.6%$1.55$1.56$1.4938,552
$1.54+0.02+1.3%$1.52$1.56$1.5214,700
$1.52+0.01+0.7%$1.51$1.548$1.4810,900
Ticker
NASDAQ:OKYO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All OKYO Pharma Limited news

OKYO Pharma Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
35 in the last 12 months · 42 in all · newest Nov 12, 2026 · oldest 2025
Decks
15 decks · latest Feb 13, 2026

Where OKYO Pharma Limited is listed

ListingExchangeCountryCurrency
NASDAQ:OKYO · Home listing · This pageNASDAQUnited StatesUSD
gettex:OK11gettexGermanyEUR
BOATS:OKYOBOATSUnited StatesUSD
Munich:OK11MunichGermanyEUR

Valuation

Price/book 4.5× against a median of 1.8×: 8th lowest of 9 Biotechnology companies shown. Statements: Year to Mar 31, 2026 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$35.56M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
4.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.02

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
OKYO Pharma Limited · NASDAQ:OKYOUS$56.15MUS$35.56Mn/an/an/a4.5×n/a0.0×1.02
iNtRON Biotechnology, Inc. · KRX:048530US$57.38MUS$31.38Mn/a5.8×n/a1.2×−142.6%0.0×n/a
HeXun Biosciences Co Ltd · TPEX:6986US$57.20MUS$32.05M16.2×3.4×6.5×1.8×37.7%0.0×n/a
Tenax Therapeutics, Inc. · NASDAQ:TENXUS$56.92M−US$56.78Mn/an/an/a0.5×n/a0.0×1.35
Kazia Therapeutics Ltd · NASDAQ:KZIAUS$56.22MUS$10.36Mn/a373×n/a1.8×n/a0.0×2.31
Gwo Xi Stem Cell Applied Technology Co., Ltd. · TPEX:6704US$55.77MUS$51.65Mn/a9.1×n/a2.5×−43.0%0.3×n/a
EyeGene, Inc. · KRX:185490US$55.57MUS$26.66Mn/a8.0×n/a1.5×−391.5%0.0×n/a
Cognition Therapeutics, Inc. · NASDAQ:CGTXUS$55.37MUS$25.10Mn/an/an/a1.9×n/a0.0×2.28
AB Science SA · EURONEXT:ABUS$55.19MUS$50.54Mn/a39.2×n/an/a−132.6%n/an/a
Azora Therapeutics, Inc. · NASDAQ:AZRUS$55.00MUS$33.00Mn/an/an/an/an/an/a1.00
Island Pharmaceuticals Ltd · ASX:ILAUS$54.84MUS$46.32Mn/a248×n/a6.2×n/a0.0×n/a
Median of the othersUS$55.67MUS$31.71M16.2×9.1×6.5×1.8×−132.6%0.0×1.82

Forecasts

2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
8.33 USD · Analysts' mean
EPS, year to Mar 2027
-0.12 · 1 analyst

Team and board

Officers

OfficerRole
Robert DempseyChief Executive Officer/Director
Keeren ShahChief Financial Officer
Paul SpencerBusiness Development and Investor Relations
Flavio MantelliChief Medical Officer
Gary JacobChief Development Officer/Director
Raj PatilChief Scientific Officer

Board

DirectorRole
Gabriele CerroneNon-Executive Chairman
Bernard DenoyerNon-Executive Director
Gary JacobChief Development Officer/Director
John BrancaccioNon-Executive Director
Robert DempseyChief Executive Officer/Director
Willy SimonNon-Executive Director

Events

QuarterResultsShare move
Quarter to Dec 31, 2025Feb 25, 2026+3.0%
Q1 2026Aug 5, 2025−1.3%
Q3 2025Jan 29, 2025+6.2%
Q1 2025Jul 30, 2024−1.6%
Q3 2024Jan 9, 2024 · After close−4.0%
Q2 2024Dec 28, 2023 · Before open+2.7%
Q1 2024Aug 15, 2023 · Before open+3.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (February 2026)Investor deck28 slidesFeb 13, 2026
Investor Presentation (June 2025)Investor deck23 slidesJune 2025
Investor Presentation (July 2024)Investor deck36 slidesJuly 2024
Investor Presentation (May 2024)Investor deck37 slidesMay 2024
Eyecelerator Conference (April 2024)Conference14 slidesApr 4, 2024
Biotech Showcase 2024Conference22 slidesJan 9, 2024
Investor Presentation (October 2023)Investor deck23 slidesOctober 2023
Investor Presentation (September 2023)Investor deck21 slidesSeptember 2023
Investor Presentation (July 2023)Investor deck27 slidesJuly 2023
Investor Presentation (June 2023)Investor deck25 slidesJune 2023
All 15 decks
DeckKindSlidesDate
Investor Presentation (May 2023)Investor deck25 slidesMay 2023
Investor Presentation (January 2023)Investor deck25 slidesJanuary 2023
Investor Presentation (May 2022)Investor deck22 slidesMay 2022
West African Minerals — Mining Indaba 2016Conference18 slidesFeb 5, 2016
West African Minerals — Investment Discovery Forum - Mining Indaba 2015Conference20 slidesFebruary 2015

Open Decks

Financings

RaiseDate
Public offering of ordinary shares
Announced: US$20M–US$23M · US$1.85 a share · Piper Sandler & Co.
Dealers: Piper Sandler & Co. (lead)
Use of proceeds: Clinical development of its product candidates, general corporate purposes and working capital
Feb 13, 2026
At-the-market programme of common shares
Announced: Leerink Partners LLC
Dealers: Leerink Partners LLC (lead)
Use of proceeds: Support ongoing clinical development and corporate objectives
Feb 11, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$4.00 an ADS on May 16, 2022.

Price
US$4.00 an ADS
ADSs offered
625,000 American depositary shares
Offering size
US$2.5 million
Underwriters' option
Up to 93,750 more ADSs
Listing
OKYO on the Nasdaq Capital Market
Underwriter
ThinkEquity
ADSs delivered
On or about May 19, 2022

Steps

StepWhen
Draft sent to the SEC in confidenceMar 22, 2021
Filed publiclyMar 4, 2022
Amended 6 timesNewest May 13, 2022
Shares registered with an exchangeMay 10, 2022
Declared effective by the SECMay 16, 2022
Final prospectus, with the priceMay 18, 2022

Open IPO · From the cover of the final prospectus (424B4) filed May 18, 2022

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue00000000
Cost of revenue6.69M2.56K7.51M6.75M13.0K811.5K5.97K219
Gross profit-6.69M-2.56K-7.51M-6.75M-13.0K-811.5K-5.97K-219
Research and development1.81M2.25M8.24M6.34M1.61M348.3K518.1K3.04M
Selling, general and administrative4.92M886.9K573.4K363.2K
Operating income-8.50M-7.19M-15.7M-13.1M-6.23M-4.13M-1.52M-4.54M-28.3M-363.3K
Depreciation and amortization1.82K2.56K3.87K3.80K2.42K1.51K2122181.04M364.8K
EBITDA-8.50M-7.19M-15.7M-13.1M-6.23M-4.13M-1.52M-4.54M-27.2M1.54K
Interest expense473.9K878.2K1.05M96.7K01.12K1.16K003.54K
Income before tax-8.94M-7.97M-16.8M-13.3M-6.22M-3.38M-1.62M-4.90M-28.3M-241.9K
Income tax7.99K3.26M-22.4K12.2K786.5K25.0K76.3K-172.0K1-100.8K
Net income-8.95M-4.71M-16.8M-13.3M-5.43M-3.35M-1.54M-4.89M-28.3M-241.9K
Earnings per share, basic-0.24-0.20-0.57-0.61-0.36-0.32-0.17-0.62-4.80-0.04
Earnings per share, diluted-0.20-0.57-0.61-0.36-0.32

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents14.6M1.56M826.8K4.05M2.70M6.89M235.5K627.6K2.01M3.93M
Short-term investments6.00M016.9M
Receivables170.7K1.89M580.9K592.2K813.0K43.4K326.2K111.4K48153.9K
Inventory170.3K-1.49K34-7921264.59K
Current assets21.0M3.68M1.54M5.20M4.30M6.99M566.7K758.8K4816.9M
Property, plant and equipment2.04K3.35K7.22K5.22K6.06K24.8K847
Goodwill535.4K
Total assets21.0M3.68M1.54M5.20M4.30M7.09M597.4K759.9K2.01M27.8M
Accounts payable7.14M8.37M7.06M4.26M1.31M1.67M593.7K381.8K141.8K
Current liabilities8.64M9.23M7.42M7.26M1.35M1.71M710.7K426.7K91.1K258.8K
Total debt2.22M98.8K25.6K
Total liabilities8.64M9.23M7.42M7.26M1.35M1.77M737.2K426.7K91.1K258.8K
Shareholders' equity12.3M-5.55M-5.88M-2.05M2.95M5.32M-140.1K333.1K1.92M27.5M
Shares outstanding37.4M39.5M29.3M22.3M15.1M10.3M9.16M7.91M5.89M5.86M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-5.94M-1.81M-9.49M-7.70M-5.47M-1.60M-1.20M-1.99M-1.59M-651.3K
Capital spending-6.08K-1.21K-3-5.92K-1.67K-6.94K-5.03K-1.32K-1.01K-375.4K
Free cash flow-5.94M-1.81M-9.49M-7.70M-5.47M-1.61M-1.20M-1.99M-1.59M-1.03M
Cash from investing-6.01M-1.21K-5.92K-1.67K-18.1K-132.7K-1.32K-1.01K-375.4K
Cash from financing25.0M2.66M6.21M9.32M2.15M7.83M963.3K774.3K774.3K4.42K
Change in cash13.0M843.6K-3.28M1.62M-3.32M6.21M-371.4K-1.99M-1.59M-651.3K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 20, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2026Current reportSEC
6-K · Report of a foreign issuerNov 5, 2026Current reportSEC
6-K · Report of a foreign issuerOct 6, 2026Current reportSEC
6-K · Report of a foreign issuerSep 29, 2026Current reportSEC
6-K · Report of a foreign issuerSep 9, 2026Current reportSEC
6-K · Report of a foreign issuerSep 8, 2026Current reportSEC
20-F/A · Annual report, amendedAug 7, 2026Annual reportSEC
4/A · Change in ownership, amendedAug 7, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 7, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4/A · Change in ownership, amendedAug 7, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 7, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 7, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 7, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 7, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 29, 2026Insider tradeSEC
6-K · Report of a foreign issuerJul 28, 2026Current reportSEC
6-K · Report of a foreign issuerJul 27, 2026Current reportSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
6-K · Report of a foreign issuerJul 23, 2026Current reportSEC
6-K · Report of a foreign issuerJul 23, 2026Current reportSEC
4 · Change in ownershipJul 22, 2026Insider tradeSEC
6-K · Report of a foreign issuerJul 22, 2026Current reportSEC
6-K · Report of a foreign issuerJul 22, 2026Current reportSEC
6-K · Report of a foreign issuerJul 22, 2026Current reportSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
6-K · Report of a foreign issuerJul 21, 2026Current reportSEC
6-K · Report of a foreign issuerJul 21, 2026Current reportSEC
6-K · Report of a foreign issuerJul 20, 2026Current reportSEC
20-F · Annual reportJul 20, 2026Annual reportSEC
6-K · Report of a foreign issuerJul 8, 2026Current reportSEC
6-K · Report of a foreign issuerJul 7, 2026Current reportSEC
3 · Initial statement of ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 1, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 1, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 22, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 22, 2026Insider tradeSEC
6-K · Report of a foreign issuerMay 19, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerApr 29, 2026Current reportSEC
6-K · Report of a foreign issuerApr 7, 2026Current reportSEC
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 18, 2026Current reportSEC
6-K · Report of a foreign issuerMar 12, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 23, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2026Big-stake noticeSEC
424B5 · ProspectusFeb 17, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 13, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 13, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 12, 2026Current reportSEC
424B5 · ProspectusFeb 12, 2026Offer documentSEC
6-K · Report of a foreign issuerFeb 11, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 11, 2026Other filingsSEC
6-K · Report of a foreign issuerFeb 10, 2026Current reportSEC
424B5 · ProspectusFeb 10, 2026Offer documentSEC
6-K · Report of a foreign issuerFeb 10, 2026Current reportSEC
UPLOAD · Letter from the SECFeb 6, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 6, 2026Other filingsSEC
F-3 · Registration statementFeb 2, 2026Offer documentSEC
6-K · Report of a foreign issuerJan 30, 2026Current reportSEC
6-K · Report of a foreign issuerJan 30, 2026Current reportSEC
6-K · Report of a foreign issuerJan 28, 2026Current reportSEC
6-K · Report of a foreign issuerJan 23, 2026Current reportSEC
6-K · Report of a foreign issuerJan 5, 2026Current reportSEC
6-K · Report of a foreign issuerDec 19, 2025Current reportSEC
6-K · Report of a foreign issuerDec 15, 2025Current reportSEC
6-K · Report of a foreign issuerDec 11, 2025Current reportSEC
6-K · Report of a foreign issuerDec 3, 2025Current reportSEC
6-K · Report of a foreign issuerNov 21, 2025Current reportSEC
6-K · Report of a foreign issuerNov 18, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 29, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerOct 29, 2025Current reportSEC
6-K · Report of a foreign issuerOct 16, 2025Current reportSEC
6-K · Report of a foreign issuerSep 22, 2025Current reportSEC
20-F/A · Annual report, amendedAug 12, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
20-F · Annual reportJul 18, 2025Annual reportSEC
6-K · Report of a foreign issuerJul 17, 2025Current reportSEC
6-K · Report of a foreign issuerJul 16, 2025Current reportSEC
6-K · Report of a foreign issuerJun 11, 2025Current reportSEC
424B5 · ProspectusJun 10, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeMay 27, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerMay 19, 2025Current reportSEC
6-K · Report of a foreign issuerMay 1, 2025Current reportSEC
6-K · Report of a foreign issuerApr 30, 2025Current reportSEC
6-K · Report of a foreign issuerMar 31, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeMar 18, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerMar 10, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 12, 2025Current reportSEC
6-K · Report of a foreign issuerJan 31, 2025Current reportSEC
6-K · Report of a foreign issuerJan 29, 2025Current reportSEC
6-K · Report of a foreign issuerJan 22, 2025Current reportSEC
6-K · Report of a foreign issuerNov 26, 2024Current reportSEC
6-K · Report of a foreign issuerOct 30, 2024Current reportSEC
6-K · Report of a foreign issuerOct 23, 2024Current reportSEC
6-K · Report of a foreign issuerOct 16, 2024Current reportSEC
6-K · Report of a foreign issuerSep 10, 2024Current reportSEC
6-K · Report of a foreign issuerSep 5, 2024Current reportSEC
6-K · Report of a foreign issuerAug 27, 2024Current reportSEC
6-K · Report of a foreign issuerAug 23, 2024Current reportSEC
6-K · Report of a foreign issuerAug 23, 2024Current reportSEC
6-K · Report of a foreign issuerAug 21, 2024Current reportSEC
6-K · Report of a foreign issuerAug 15, 2024Current reportSEC
20-F · Annual reportAug 13, 2024Annual reportSEC
6-K · Report of a foreign issuerAug 6, 2024Current reportSEC
NT 20-FJul 31, 2024Explanation requestSEC
6-K · Report of a foreign issuerJul 11, 2024Current reportSEC
6-K · Report of a foreign issuerJul 10, 2024Current reportSEC
6-K · Report of a foreign issuerJul 10, 2024Current reportSEC
6-K · Report of a foreign issuerMay 8, 2024Current reportSEC
6-K · Report of a foreign issuerApr 30, 2024Current reportSEC
6-K · Report of a foreign issuerApr 8, 2024Current reportSEC
6-K · Report of a foreign issuerApr 4, 2024Current reportSEC
6-K · Report of a foreign issuerApr 2, 2024Current reportSEC
6-K · Report of a foreign issuerMar 29, 2024Current reportSEC
6-K · Report of a foreign issuerMar 22, 2024Current reportSEC
6-K · Report of a foreign issuerMar 21, 2024Current reportSEC
6-K · Report of a foreign issuerMar 20, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 9, 2024Current reportSEC
6-K · Report of a foreign issuerJan 31, 2024Current reportSEC
6-K · Report of a foreign issuerJan 8, 2024Current reportSEC
6-K · Report of a foreign issuerJan 5, 2024Current reportSEC
6-K · Report of a foreign issuerDec 21, 2023Current reportSEC
424B5 · ProspectusDec 20, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 18, 2023Current reportSEC
424B5 · ProspectusDec 15, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 4, 2023Current reportSEC
6-K · Report of a foreign issuerNov 29, 2023Current reportSEC
6-K · Report of a foreign issuerNov 1, 2023Current reportSEC
424B5 · ProspectusOct 31, 2023Offer documentSEC
4 · Change in ownershipOct 31, 2023Insider tradeSEC
6-K · Report of a foreign issuerOct 31, 2023Current reportSEC
6-K · Report of a foreign issuerOct 10, 2023Current reportSEC
6-K · Report of a foreign issuerOct 5, 2023Current reportSEC
4 · Change in ownershipSep 28, 2023Insider tradeSEC
6-K · Report of a foreign issuerSep 15, 2023Current reportSEC
6-K · Report of a foreign issuerSep 15, 2023Current reportSEC
424B5 · ProspectusSep 15, 2023Offer documentSEC
6-K · Report of a foreign issuerSep 14, 2023Current reportSEC
6-K · Report of a foreign issuerSep 14, 2023Current reportSEC
424B5 · ProspectusSep 13, 2023Offer documentSEC
6-K · Report of a foreign issuerSep 13, 2023Current reportSEC
6-K · Report of a foreign issuerSep 8, 2023Current reportSEC
6-K · Report of a foreign issuerAug 30, 2023Current reportSEC
6-K · Report of a foreign issuerAug 29, 2023Current reportSEC
20-F/A · Annual report, amendedAug 25, 2023Annual reportSEC
6-K · Report of a foreign issuerAug 15, 2023Current reportSEC
20-F · Annual reportAug 14, 2023Annual reportSEC
NT 20-FJul 31, 2023Explanation requestSEC
6-K · Report of a foreign issuerJul 31, 2023Current reportSEC
FWP · Free writing prospectusJul 28, 2023Offer documentSEC
6-K · Report of a foreign issuerJul 28, 2023Current reportSEC
424B5 · ProspectusJul 28, 2023Offer documentSEC
6-K · Report of a foreign issuerJul 28, 2023Current reportSEC
6-K · Report of a foreign issuerJul 28, 2023Current reportSEC
6-K · Report of a foreign issuerJul 27, 2023Current reportSEC
424B3 · ProspectusJun 15, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 15, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveJun 15, 2023Other filingsSEC
CORRESP · Letter to the SECJun 12, 2023Other filingsSEC
CORRESP · Letter to the SECJun 12, 2023Other filingsSEC
UPLOAD · Letter from the SECJun 12, 2023Other filingsSEC
F-1/A · Registration statement, amendedJun 9, 2023Offer documentSEC
F-1/A · Registration statement, amendedJun 8, 2023Offer documentSEC
F-3 · Registration statementJun 8, 2023Offer documentSEC
6-K · Report of a foreign issuerJun 6, 2023Current reportSEC
CORRESP · Letter to the SECJun 2, 2023Other filingsSEC
F-1/A · Registration statement, amendedJun 2, 2023Offer documentSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedJun 2, 2023Other filingsSEC
UPLOAD · Letter from the SECMay 30, 2023Other filingsSEC
6-K · Report of a foreign issuerMay 22, 2023Current reportSEC
6-K · Report of a foreign issuerMay 19, 2023Current reportSEC
F-1 · Registration statementMay 17, 2023Offer documentSEC
6-K · Report of a foreign issuerMay 15, 2023Current reportSEC
6-K · Report of a foreign issuerMay 11, 2023Current reportSEC
6-K · Report of a foreign issuerMay 11, 2023Current reportSEC
6-K · Report of a foreign issuerMay 3, 2023Current reportSEC
6-K · Report of a foreign issuerMay 3, 2023Current reportSEC
6-K · Report of a foreign issuerMay 3, 2023Current reportSEC
6-K · Report of a foreign issuerMay 2, 2023Current reportSEC

This page holds 200 of 313 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from OKYO Pharma Limited’s releases · as of Feb 13, 2026

Common shares
52,479,527
Fully diluted
52,479,527

Fully diluted

LineShares
Common shares52,479,527

Share count over time

CountShares
Nov 22, 202652,479,527

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
Fidelity Nasdaq Composite Index Fund12,090US$20,795May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Patil Rajkumar V.
Officer: Chief Scientific Officer
Buy3,363USD 1.49US$5,011Jul 27, 2026
Dempsey Robert John
Director, Officer: CHIEF EXECUTIVE OFFICER
Buy15,000USD 1.54US$23,100Jul 22, 2026
Cerrone Gabriele M
Director, 10% owner
Buy22,500USD 1.45US$32,625Jul 21, 2026
Mantelli Flavio
Officer: CHIEF MEDICAL OFFICER
Buy20,000USD 1.40US$28,000Jul 21, 2026
Jacob Gary S
Director, Officer: CHIEF DEVELOPMENT OFFICER
Buy3,500USD 1.40US$4,900Jul 21, 2026
Brancaccio John P
Director
Buy5,000USD 1.48US$7,400Jul 21, 2026
Cerrone Gabriele M
Director, 10% owner
Buy25,000USD 1.40US$35,000Jul 20, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gary Jacob
Other companies: Virpax Pharmaceuticals, Inc. (Director · Feb 16, 2021 – Jan 1, 2022 · Past); Hepion Pharmaceuticals, Inc. (Director · Oct 7, 2013 – Feb 19, 2024 · Past); Callisto Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 17, 2013 – Jan 17, 2013 · Past); Cardiff Oncology, Inc. (Director · Jan 23, 2012 – Mar 23, 2021 · Past); Synergy Pharmaceuticals Inc (Executive Chairman, Director · Dec 6, 2011 – Jun 15, 2018 · Past)
Chief Development Officer/Director · Since at least May 16, 2022
Gabriele Cerrone
Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 5, 2026); Tiziana Life Sciences Ltd (Executive Chairman · Since at least Jun 15, 2026)
Non-Executive Chairman · Since at least Jul 21, 2026
John Brancaccio
Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 5, 2026); Tiziana Life Sciences Ltd (Non-Executive Director · Since at least Nov 5, 2026)
Non-Executive Director · Since at least Mar 18, 2026
Keeren Shah
Other companies: Tiziana Life Sciences Ltd (Chief Operating Officer & Chief Financial Officer · Since at least Mar 18, 2026); Accustem Sciences Inc (Chief Finance Officer · Since at least Dec 1, 2021)
Chief Financial Officer · Since at least May 16, 2022
Willy Simon
Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 4, 2026); Tiziana Life Sciences Ltd (Non-Executive Director · Since at least Nov 4, 2026)
Non-Executive Director · Since at least Nov 4, 2026
Paul Spencer
Other companies: Tiziana Life Sciences Ltd (Business Development, and Investor Relations · Since at least Oct 21, 2026)
Business Development and Investor Relations · Since at least Oct 6, 2026
Bernard DenoyerNon-Executive Director · Since at least Mar 18, 2026
Flavio MantelliChief Medical Officer · Since at least Feb 10, 2026
Rajkumar V PatilChief Scientific Officer · Since at least Mar 18, 2026
Raj PatilChief Scientific Officer · Since at least Jul 28, 2026
All 11 people
PersonSeat
Robert DempseyChief Executive Officer/Director · Since at least Jul 22, 2026

Open People

Log in to ask 6ix AI your own questions about OKYO Pharma Limited.